Story perspectives

Takeda Secures $11.4B Deal for Cancer Therapies

10/22/2025

50 7

Summary

Story summary

Innovent Biologics and Takeda Pharmaceutical Co. agreed to an $11.4 billion licensing deal giving Takeda rights to three cancer therapies.
The three therapies include IBI363 and IBI343, both in late-stage trials, and Takeda will lead development in the United States.
The deal provides an upfront payment of $1.2 billion and includes potential milestone payments.
The collaboration strengthens Takeda's oncology portfolio for non-small cell lung cancer and gastric cancers.

1 of 1

Story summary

Innovent Biologics and Takeda Pharmaceutical Co. agreed to an $11.4 billion licensing deal giving Takeda rights to three cancer therapies.
The three therapies include IBI363 and IBI343, both in late-stage trials, and Takeda will lead development in the United States.
The deal provides an upfront payment of $1.2 billion and includes potential milestone payments.
The collaboration strengthens Takeda's oncology portfolio for non-small cell lung cancer and gastric cancers.